A Bold Initiative Left Adrift
Launched in June 2025, the Commissioner’s National Priority Voucher program aimed to cut reviews to one to two months for therapies addressing national priorities, such as urgent unmet health needs. Once touted as a bold fix for US pharmaceutical regulation, the program has been left adrift, reflecting the internal turmoil at an agency that has been without a commissioner since May.
One source said FDA leadership had told companies the agency was not moving forward with the program but was keeping applications open; submissions are accepted but do not advance. Rich Danker, a former assistant secretary at the Department of Health and Human Services (HHS), said the initiative is quietly being phased out. HHS spokesperson Emily Hilliard, by contrast, said the pilot is ongoing and that the FDA is reviewing feedback from a June public hearing to refine the framework.
The Program in Numbers
Internal documents show the state of the program after more than a year:
- 22 drugs received priority vouchers, of which 12 have been approved, including five since Makary left.
- For several drugs, the program sped approval by eight months or more.
- No new drugs have received a voucher since May, and the executive council of political appointees has gone dormant.

















